"The first oral extended adjuvant therapy reducing the risk of recurrence and brain metastases of HER2 positive breast cancer"

Neratinib, an oral HER2 targeted therapy, was approved by the U.S. Food and Drug Administration in 2017 and by the European Commission in 2018. It has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for early and metastatic breast cancer.  Neratinib, developed as a small molecule, passes through the Blood Brain Barrier (BBB) overcoming the limitation in the treatment and prevention of brain metastases as a next generation therapy.






"The first oral extended adjuvant therapy reducing the risk of recurrence and brain metastases of HER2 positive breast cancer"


Neratinib, an oral HER2 targeted therapy, was approved by the U.S. Food and Drug Administration in 2017 and by the European Commission in 2018. It has been included as a recommended treatment option in the latest National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for early and metastatic breast cancer.  Neratinib, developed as a small molecule, passes through the Blood Brain Barrier (BBB) overcoming the limitation in the treatment and prevention of brain metastases as a next generation therapy.

Irreversible pan-HER tyrosine kinase inhibitor


USA, Canada, EU, Australia, New Zealand, Singapore, China, Hong Kong, Taiwan, Malaysia, Brunei, Israel, Argentina, Ecuador, Chile, Switzerland, Peru

Irreversible pan-HER tyrosine kinase inhibitor


Regulatory Approval Countries

USA, Canda, EU, Australia, New Zealand, Singapore, China, Hong Kong, Taiwan, Malaysia, Brunei, Israel, Argentina, Ecuador, Chile, Switzerland, Peru


Development Timeline

Copyright 2021 - BIXINK   │   Terms of Use

 Contact   │   Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, 

Republic of Korea

Copyright 2021 - BIXINK │ Terms of Use │ Contact  │  Privacy

6F, 292 Gangnam-daero, Gangnam-gu, Seoul 06258, Republic of Korea